



Concept Paper

Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group [†]

Samuel Shor ^{1,*}, Christine Green ², Beatrice Szantyr ³, Steven Phillips ⁴, Kenneth Liegner ^{5,6,7}, Joseph Burrascano Jr. ⁸, Robert Bransfield ⁹  and Elizabeth L. Maloney ¹⁰

¹ Internal Medicine of Northern Virginia, George Washington University Health Care Sciences', 1860 Town Center Drive #G220, Reston, VA 20191, USA

² Family Medicine, Green Oaks Medical Center, Mountain View, CA 94040, USA; drchrisg@gmail.com

³ Internal Medicine, Pediatrics and Adolescent Medicine, P.O. Box 549, Lincoln, ME 04457, USA; bszantyr@gmail.com

⁴ Internal Medicine Private Practice 944 Danbury Road, Wilton, CT 06897, USA; sephillips18@gmail.com

⁵ 592 Route 22-Suite 1B, Pawling, NY 12564, USA; kbliegnermd@optonline.net

⁶ Northwell Hospital Systems, Northern Westchester Hospital, Mount Kisco, NY 10549, USA

⁷ Nuvance Hospital Systems, Sharon Hospital, Sharon, CT 06069, USA

⁸ Superior Biologics, NY 10532, USA; burraj69@gmail.com

⁹ Department of Psychiatry Rutgers, RWJ Medical School, 225 Highway 35, Ste 107 Red Bank, Monmouth, NJ 07701, USA; bransfield@comcast.net

¹⁰ Partnership for Tick-borne Diseases Education, P.O. Box 84 Wyoming, MN 55092, USA; ptde.emaloney@gmail.com

* Correspondence: samshor@yahoo.com; Tel.: +1-703-709-1119

† International Lyme and Associated Diseases Society.

Received: 8 October 2019; Accepted: 11 December 2019; Published: 16 December 2019



Abstract: *Objective:* Chronic Lyme disease has been a poorly defined term and often dismissed as a fictitious entity. In this paper, the International Lyme and Associated Diseases Society (ILADS) provides its evidence-based definition of chronic Lyme disease. *Definition:* ILADS defines chronic Lyme disease (CLD) as a multisystem illness with a wide range of symptoms and/or signs that are either continuously or intermittently present for a minimum of six months. The illness is the result of an active and ongoing infection by any of several pathogenic members of the *Borrelia burgdorferi sensu lato* complex (*Bbsl*). The infection has variable latency periods and signs and symptoms may wax, wane and migrate. CLD has two subcategories, CLD, untreated (CLD-U) and CLD, previously treated (CLD-PT). The latter requires that CLD manifestations persist or recur following treatment and are present continuously or in a relapsing/remitting pattern for a duration of six months or more. *Methods:* Systematic review of over 250 peer reviewed papers in the international literature to characterize the clinical spectrum of CLD-U and CLD-PT. *Conclusion:* This evidence-based definition of chronic Lyme disease clarifies the term's meaning and the literature review validates that chronic and ongoing *Bbsl* infections can result in chronic disease. Use of this CLD definition will promote a better understanding of the infection and facilitate future research of this infection.

Keywords: Lyme disease; *Borrelia* infection; borreliosis; chronic Lyme; CLD; untreated Lyme; neuroborreliosis; late Lyme; persistent Lyme disease; post-treatment Lyme disease syndrome (PTLDS)

1. Introduction

Lyme disease, resulting from an active infection with any of several pathogenic members of the *Borrelia burgdorferi sensu lato* complex (*Bbsl*), often affects multiple systems. It is the most common vector-borne illness in the United States [1] and Europe [2]. The Centers for Disease Control and

Prevention (CDC) estimates that the annual incidence of Lyme disease in the United States exceeds 329,000 [3].

It is well-documented that many patients present with manifestations of late disease prior to receiving antibiotic therapy and investigators in the field have long known that the illness can be chronic [1,4–6]. While a history of a known blacklegged tick bite or erythema migrans (EM) rash allows for a timely diagnosis, few patients were aware of a tick bite prior to infection [7,8] and the incidence of EM rashes varies by geographic location and Borrelial species such that some patients never develop an EM [1,8,9]. Thus, chronic manifestations of Lyme disease may result from diagnostic delays. Chronic manifestations of Lyme disease may also result from failed antibiotic therapy as commonly prescribed regimens can be non-curative [4,10–15]. Researchers have documented that patients with acute and/or long-standing Lyme disease frequently remain ill for prolonged periods of time following treatment and that some experience disease progression despite treatment [4,15–18].

Chronic manifestations of Lyme disease are associated with significant and long-standing quality-of-life (QoL) impairments in some patients [16–20]. QoL scores of participants in the four National Institutes of Health (NIH)-sponsored Lyme disease retreatment trials were consistently worse than those of healthy populations [16–18]. In two of these trials, persistent symptoms were of such severity that they interfered with daily functioning [17]. Patients in a third trial had pain levels on par with postsurgical patients, fatigue comparable to that of multiple sclerosis patients and physical functioning similar to patients with congestive heart failure [16]. A detailed table of quality of life impairments in the NIH subjects was included in the 2014 ILADS treatment guidelines [12]. Additionally, although post-mortem determination of cause of death can be challenging, there have been reported fatalities in which *B. burgdorferi* infection was the underlying cause of death [21–24].

The economic impact of chronic manifestations of Lyme disease can be substantial. Survey responses from patients diagnosed with Lyme disease (based on CDC surveillance case criteria) who had been ill for 6 or more months, found that 39.4% and 28.3%, respectively, stopped or reduced their work hours or role and 37.3% spent at least \$5000 on Lyme-related out-of-pocket expenses [25]. A study employing a medical insurance claims database also documented the financial consequences of chronic manifestations [26]. Of the 52,795 individuals diagnosed and treated for Lyme disease, total costs over a 12-month post-treatment period for patients who had one or more post-treatment Lyme disease symptoms were \$3798 higher than for those who had none.

Despite the significant impact that chronic manifestations of Lyme disease can have on individuals, their families and the economy, there remains no widely accepted definition of chronic Lyme disease (CLD). A recently proposed definition divides CLD into two categories, treated and untreated [27]. The International Lyme and Associated Diseases Society (ILADS) generally agrees with that approach. Other authors proposed using the term Lyme-MSIDS (Multiple Systemic Infectious Disease Syndrome) for patients who were previously labeled as having either chronic Lyme disease or post-treatment Lyme disease syndrome (PTLDS) [28]. The purpose of this paper is to establish the International Lyme and Associated Diseases Society's definition of chronic Lyme disease. Our immediate goal for the definition is to promote a better understanding of the infection by establishing that chronic and ongoing *Bbsl* infection can result in chronic disease. Intermediate and long-term goals are to facilitate clinical research of this infection and to improve access to care for patients with chronic Lyme disease.

2. Chronic Lyme Disease Definition

ILADS defines chronic Lyme disease (CLD) as a multisystem illness with a wide range of symptoms and/or signs that are either continuously or intermittently present for a minimum of six months. The illness is the result of an active and ongoing infection by any of several pathogenic members of the *Borrelia burgdorferi sensu lato* complex. The infection has variable latency periods and signs and symptoms may wax, wane and migrate. CLD has two subcategories: CLD, untreated (CLD-U) and CLD, previously treated (CLD-PT). The latter requires that CLD manifestations persist

or recur following treatment and are present continuously or in a relapsing/remitting pattern for a duration of six months or more.

The definition's required minimum six-month duration is consistent with the definitions of other chronic infections [29,30]. While CLD can be complicated by the presence of other tick-borne pathogens [31,32], the definition does not require the presence of a co-infecting pathogen. Similarly, it is important to recognize that persistent manifestations of Lyme disease following antibiotic therapy wax and wane such that an individual's functional performance can vary significantly over time. Although many patients with persistent manifestations of Lyme disease following treatment are functionally impaired at some point in their illness, others will not meet the criteria for functional impairment [33]. Therefore, functional status is not a component of the definition.

ILADS' definition of CLD, although similar to the previously offered CLD definition, differs on several key points. Both definitions have two subcategories and both require that symptoms be present for a minimum of six months. Given that acute Lyme disease, by definition, is caused by pathogenic members of the *Bbsl* complex, ILADS limits the list of potential pathogens to those bacteria while the other definition appears to include other pathogens as causative agents: "CLD may be caused by any of the known pathogenic *Borrelia* genospecies and associated TBD pathogens including *Babesia*, *Anaplasma*, *Ehrlichia*, *Rickettsia*, *Powassan virus* and possibly *Bartonella*" [27]. In addition, the CLD-T definition is said to describe patients who were previously treated for TBDs yet have "functionally significant fatigue, musculoskeletal pain, cardiovascular disease, and/or neuropsychiatric dysfunction that persists for six months or more." In contrast, the ILADS definition of CLD-PT requires prior treatment specifically for Lyme disease, functional impairment is not required, and all of the known manifestations of Lyme disease can fulfill the definition. With regard to the proposed Lyme-MSIDS framework, we agree that many individuals infected with a pathogenic *Bbsl* species also may have or develop multiple systemic issues that may confound the clinical picture, but in the collective experience of this working group, many do not. Like the presence of co-existing infections, when these confounding issues are present, they are clinically important, but they are not required for the definition of chronic Lyme disease.

3. Microbiology

CLD may be caused by any one of several known pathogenic species in the *Bbsl* complex [34–50]. In the United States, Lyme disease is primarily caused by *Borrelia burgdorferi sensu stricto* (*Bbss*). In Europe, *Borrelia afzelii*, *Borrelia garinii* and *Bbss* cause the majority of cases [32]. Additional *Bbsl* species are known to cause Lyme-like illnesses but the pathogenic capabilities of other *Bbsl* species have not been fully characterized [43,51–57]. Please see Appendix A for a list of identified *Bbsl* species and their status as a human pathogen. Unlike the *Bbsl* pathogens, *Borrelia miyamotoi*, a member of the relapsing fever group of *Borrelia*, is associated with recurrent fevers and rarely produces erythema migrans lesions [58]. *Bbsl* genospecies and strains within a given species differ in terms of expressed antigens, disease presentations and response to antibiotics [42,49,59,60]. These differences introduce diagnostic uncertainties and provide additional unknowns as to optimal antibiotic regimens, thereby increasing the risk of developing CLD.

4. Vector

Nymphal and adult *Ixodes* ticks are the primary vectors of Lyme disease. In the United States, transmission occurs via *Ixodes scapularis* in the Eastern and Midwestern states and *Ixodes pacificus* in the western states [51], *Ixodes ricinus* is the European vector and *Ixodes persulcatus* is the Eurasian vector [61–63]. *Ixodes* ticks prefer wooded or brushy areas, and exposure risk is correspondingly high in these areas [64,65]. Contact with reservoir or incidental hosts, including pets, can result in tick exposure without habitat incursion. Migratory birds are responsible for long-range dispersal and transporting ticks to previously designated non-endemic locales [66–68]. *Ixodes* ranges are expanding, which increases the overall risk of exposure [69].

The timing of nymph and adult activity varies by climate zone [70]. Annual case reports in the USA peak during June through August, which coincides with the peak activity of nymphal ticks in the Northeast and Midwest [51]. Adult ticks are active throughout the balance of the year.

5. Pathophysiologic Basis of Chronic Lyme Disease

Chronic, active infections with *Bbsl* pathogens may result from delayed diagnosis (CLD-U) or ineffective antibiotic therapy (CLD-PT), or both [71–76]. Pathogenic *Bbsl* have the ability to invade a wide variety of cells and tissues, including: fibroblasts, glial and neuronal cells, endothelial cells, lymphocytes, synovium, skin, ligaments, cardiac tissue, lymph nodes and tonsillar lymphoid tissue [77–89]. Pathologic examination of infected tissues correlated clinical manifestations of CLD with the invasion of these tissues [90–92].

Literature reports and studies dating back to 1979 have documented chronic and late manifestations of active infection with *B. burgdorferi* including carditis, meningitis, cranial nerve palsy, radiculopathy, arthritis, reversible peripheral neuropathies, reversible chronic encephalopathy, polyneuropathy, leukoencephalitis, cognitive and psychiatric symptoms as well as fatigue, headache, hearing loss, tinnitus and fibromyalgia [4,92–97]. Importantly, some studies used objective assessments of pathology to confirm subjective data that lacked corresponding physical exam findings [13,92].

The etiology of persistent clinical manifestations in patients previously treated for Lyme disease continues to be debated as the pathophysiologic evidence base continues to expand and evolve. Several mechanisms, including tissue injury [98], Lyme-induced secondary conditions [99–102], unrecognized or undertreated co-infections [12,98], immune dysfunction of several types [103–108], and persistent *Bbsl* infection have been proposed [12,109,110]. Types of potential post-treatment immune dysfunction include failure to clear antigenic debris [103,104], the formation of autoantibodies [105,106] and persistent elevation of immune mediators [107,108]. It is possible that more than one mechanism may be operative in a given individual.

To this working group, the volume of animal and human evidence documenting persistent *Bbsl* infection following antibiotic therapy, a requisite component of our CLD-PT definition, is substantial, and thus, quite persuasive [7,22,23,71–74,76,83,111–140]. Persistent infection has been demonstrated in patients with Lyme disease by PCR and culture [22,23,71–74,76,83,113,118,119,121,125,126,136–140]. A xenodiagnostic study in humans, sponsored by the NIH, documented the acquisition of *B. burgdorferi* DNA by uninfected ticks which fed on a persistently symptomatic patient who had been treated for Lyme disease more than 1 year earlier [129]. Given the expectation that the immune system would typically clear bacterial debris quickly, this finding is significant and strongly supports that the infection was ongoing. Animal studies have corroborated the human findings, documenting bacterial persistence by culture, PCR, histopathologic testing of post-treatment necropsy specimens and by xenodiagnoses [130–132].

Potential survival mechanisms of *Bbsl* persistence include: immune evasion, immune modulation, and the presence of subpopulations of persister cells. Physical seclusion—within cells [84,85,141], collagen-rich tissues [142], and immunologically protected sites (CNS, joints, and eyes) [143–145], is one method of immune evasion. Biofilm generation is another recognized form of physical seclusion. Published reports document that *Borrelia burgdorferi* can produce biofilm in vitro [146] and examination of infected human tissues demonstrated *B. afzelii* [147] and *B. burgdorferi* [148] embedded in biofilm.

Immune evasion via alterations in its physical structure may also contribute to *Bbsl* survival. Such alterations include phasic and antigenic variations [149–153], producing changes in the expression of outer surface proteins (Osp), and morphologic changes leading to cell-wall deficient forms, round bodies, spherocytes and “cyst” forms [154–159].

Bbsl pathogens can modulate the effectiveness of the host immune response via altered complement [160–162], neutrophil and dendritic cell functioning [163,164], alterations in the adaptive immune response [165–167] as well as changes in cytokine and chemokine levels [105,168,169].

In addition, several researchers have published on the existence of persister populations of *Bb* [170–174]. A recently developed mouse model of Lyme arthritis resulting from infection with persister microcolony forms found that this bacterial form caused more severe arthritis than log growth spirochetal forms. Microcolony infections could not be eradicated by commonly used antibiotics for Lyme [174].

Researchers have noted that manifestations often followed an intermittent, recurrent course, that disease latency varied by system, and that symptom migration within and between systems did not follow a predictable temporal pattern [4,93–97,136,137,175–177]. These observations are consistent with detailed studies of the pathogenesis of *Borrelia* infections in mammals. In mammalian models, *B. burgdorferi* rapidly developed genetic and antigenic variations beginning within days of initial infection [149,150,178]. This antigenic variation was random, induced by host factors and increased over time. Investigators concluded that the process could potentially result in “millions” [149] of variations and contribute to *B. burgdorferi*'s immune evasion capabilities and tissue tropism. Thus, this phenomenon may underlie the changing and migratory presentation of CLD.

While some have claimed a lack of therapeutic efficacy in the NIH-sponsored antibiotic retreatment trials and use this to challenge the existence of persistent *Bbsl* infections [16–18,98,179], ILADS and several other groups reviewing the NIH-sponsored trials of antibiotic retreatment have noted problems with trial design and execution [12,110,180,181]. Had the NIH trials been without these design flaws, valid conclusions regarding the effectiveness of the specific therapeutic regimen used in each trial could have been drawn but universal conclusions regarding the effectiveness of all antibiotic regimens are beyond the scope of those trials. Therefore, conclusions regarding infection status that are based on a lack of a therapeutic response are faulty as an absent response is not proof that the subjects were not infected. Determining infection status in these circumstances is a distinctly different task, one that requires the application of a test of bacteriological cure, which is lacking in Lyme disease. Despite this, the Krupp trial which was well-designed on its fatigue endpoint, demonstrated a sustained moderate to large treatment effect in patients with severe fatigue [18], a finding that was corroborated in a post-hoc analysis of the severe fatigue patient subset of the Fallon cohort [16].

6. Clinical Manifestations of Chronic Lyme Disease

Methods


To establish literature support for the ILADS definitions of CLD-U and CLD-PT and to characterize the clinical spectrum of these entities, the working group performed an electronic search of the Medline database via PubMed on 30 April 2019, using these terms—late Lyme disease, chronic Lyme disease and chronic Lyme borreliosis and these filters—clinical trials, observational studies, comparative studies, case reports, human species, English language. Two hundred and ninety-eight papers were retrieved. The search was supplemented by additional publications referenced in the retrieved documents as well as papers known to the working group (See Figure 1).

With regard to CLD-U, retrieved papers were reviewed in order to identify manifestations and/or conditions present for 6 or more months in untreated patients who had direct laboratory evidence of *Bbsl* infection (positive culture, positive PCR (polymerase chain reaction), positive antigen detection, and/or positive microscopy with *Bb*-specific immunohistochemistry). Twenty-five papers met those parameters and these were supplemented with an additional eleven papers meeting those same parameters [71–76,106,124,138,182–208]. With regard to CLD-PT, the retrieved papers were reviewed in order to identify manifestations that were present for six months or more post-treatment in patients who had direct laboratory evidence of *Bbsl* infection (positive culture, positive PCR, positive antigen detection, and/or positive microscopy with *Bb*-specific immunohistochemistry). Seven papers met those parameters and these were supplemented with an additional twelve papers meeting those same parameters [23,71–74,76,83,113,118,119,121,125,126,136–140].

Flow Diagram for Papers included in Analysis of Chronic Lyme Disease Manifestations

Search terms: late Lyme disease, chronic Lyme disease or chronic Lyme borreliosis
 Search limits: clinical trials, observational studies, comparative studies, case reports, human species,
 English language.

Search date interval: January 1, 1982 - April 30, 2019



^a72,74,106,138,182,183,185-192,195-200,203,205-208

^b71,73,75,76,124,184,193,194,201,202,204

^c72,74,83,113,118,121,138

^d22,23,71,73,76,119,125,126,136,137,139,140

Figure 1. Flow Diagram of Literature Search.

The papers cited in Table 1; Table 2 do not lend themselves to a formal statistical analysis of the frequency of the various symptoms and signs. However, it is interesting to note that there is a strong overlap between the most commonly identified CLD-U and CLD-PT symptoms. The six CLD-U symptoms with the greatest number of supporting papers were arthralgia, fatigue, sensory changes (hypoesthesia/paresthesias), joint swelling, headache, and skin discoloration. The six CLD-PT symptoms with the greatest number of supporting papers were arthralgia, fatigue, headache, sensory changes (hypoesthesia/paresthesias/hypoalgesia) impaired memory, myalgia.

These findings closely mirror those of a recent community-based study of treated Lyme disease patients who were followed longitudinally [209]. The most commonly reported symptoms in the persistently symptomatic group included the common CLD-U and CLD-PT symptoms. A validated screening questionnaire for Lyme disease also substantiates the clinical relevance of the most common CLD-U and CLD-PT manifestations [177]. Furthermore, a study comparing reported symptoms in post-treatment Lyme disease syndrome (PTLDS) patients versus controls found that the rates of fatigue, pain, sleep disturbance, and depression were significantly higher and more severe in the PTLDS cohort [210].

Table 1. Lists the symptoms, signs and conditions conforming to CLD-U that the investigators attributed to the infection.

CLD-U: Symptoms, Signs, and Conditions in Patients with Direct Evidence of Infection		
Symptoms and Signs		
Constitutional	Skin	Cardiopulmonary
Fatigue [71,72,75,106,182–184] Fever [75] Weight gain [182]	Atrophic lesions [183] Dry skin [182] Rash, unspecified [185] Skin discoloration [182,183,186–188]	Cardiac arrhythmia [138,183,189] Dyspnea [184] Mitral regurgitation [184] Palpitations [184,192] Orthostatic Intolerance [106]
Head Ears Eyes Nose Throat (HEENT)	Musculoskeletal	Neuropsychiatric/Neurological
Blurred vision [76] Double vision [190] Progressive visual loss [72] Decreased visual acuity [191] Nystagmus [190] Photophobia [192,193] Eyelid swelling [192] Facial flushing [75] Facial pain [72,138] Tinnitus [76] Headache [74–76,189,194] Stiff neck [74,75] Hearing loss [55,189]	Arthralgia [106,182,186,195–198] Arthritis [73,75,124,183,198–201] Joint swelling [72,106,183,186,198,200] Morning stiffness [196] Muscle cramps [197] Muscle weakness [189,202] Myalgia [106,193,202] Muscle atrophy [197,199,202]	Memory difficulties [74,75,106,194] Abnormal taste [76] Dizziness [75,138] Vertigo [76] Decreased sensation [106,197,201] Paresthesias [189,190,196,201] Tingling [197] Pain, generalized [138,197] Pain radicular [76,191] Decreased dexterity [197] Abnormal gait [75,192,197,199] Abnormal balance [138,191] Limb paralysis [183] Spastic paraparesis [197] Positive Babinski [197] Areflexia [191,201] Hyperreflexia [197] Fasciculations [197] Urinary incontinence [197] Decreased concentration [106]
Conditions		
Acrodermatitis chronica atrophicans [76,182,185–188,195,196,202,203] Alzheimer’s disease [204] Anectoderma [205] Carpal tunnel syndrome [189] Cutaneous tumor [206] Dactylitis [207]	Encephalomyelitis [74,75] Encephalopathy [74,75] Endocarditis [184] Epilepsy/seizure [190,194,208] Facial palsy [74,75,193,208] Meningitis [74,75,193] Mitral regurgitation [184] Mycosis fungoides-like rash [185]	Panuveitis [76] Polyarthritis [202] Radiculoneuropathy [74,75] Sensory-motor polyneuropathy [74,197] Sensory neuropathy [75] Synovitis [189,200] Ulcerative keratitis [192]

Table 2. Lists the symptoms, signs and conditions conforming to CLD-PT that the investigators attributed to the infection.

CLD-PT: Symptoms, Signs, and Conditions in Patients with Direct Evidence of Infection		
Symptoms and Signs		
Constitutional	Skin	Cardiopulmonary
Anorexia [119] Fatigue [22,71,72,113,119,125,136] Fever [113,137,138] Weight loss [22]	Recurrent EM lesions [23,125]	
HEENT	Musculoskeletal	Neuropsychiatric/Neurological
Conjunctival irritation [72] Decreased central vision [83] Diplopia [126] Eye pain [72] Photophobia [72] Retro-orbital pain [121] Tinnitus [72] Drooling [22] Fullness in head [125] Headache [71,74,113,126,136,137] Neck pain [22] Stiff neck/torticollis [74]	Arthralgia [23,71,76,83,118,125,126,136,137] Arthritis [73,126] Hand pain [22] Joint swelling [118] Migratory pain [23,126] Muscle stiffness [22] Muscle weakness [139,140] Myalgia [125,126,138,140] Trigger finger [83]	Cognitive dysfunction [119] Poor concentration [125] Memory difficulties [22,74,119,125] Vertigo [121] Dizziness [126] Hypoalgesia [76] Hypoesthesia [76,121] Paresthesias [71,119] Radicular pain [119,137] Cogwheel rigidity [22] Tremors [22]

Table 2. Cont.

CLD-PT: Symptoms, Signs, and Conditions in Patients with Direct Evidence of Infection		
Gastrointestinal	Genitourinary	
Vomiting [76]	Nocturia [119]	
	Urge incontinence [22,119]	
	Urgency [119]	
	Urinary frequency [119]	
Conditions		
	Encephalopathy [74,126]	Pleuritis [126]
Carpel tunnel syndrome [126]	Epilepsy [126]	Radiculitis [126]
Chorioretinitis [126]	Facial palsy [74]	Radiculoneuropathy [74]
Choroiditis [83]	Hepatopathy [126]	Sensory neuropathy [74]
Depressed corneal reflexes [121]	Hemiparesis [121,126]	Tenosynovitis [83]
Encephalitis [126]	Meningismus [113]	Trigeminal sensory neuropathy [121]
Encephalomyelitis [74]	Meningitis [74,126]	Uveitis [126]
Encephalomyelorradiculopathy, recurrent [71]	Mononeuritis multiplex [121]	Vasculitis [126]
	Neuropathy [126]	
	Pericarditis [126]	

7. Comparison to the Definition of Post-Treatment Lyme Disease Syndrome

Post-treatment Lyme disease syndrome (PTLDS) and post-Lyme disease syndrome (PLDS) have been used to describe patients who remain ill following antibiotic treatment for Lyme disease [33,98]. These two terms are frequently, though imprecisely, used interchangeably. Although originally proposed as an operational definition [33], PTLDS is primarily a research definition. A recently released draft of the Infectious Diseases Society of America (IDSA)/American Academy of Neurology (AAN)/American College of Rheumatology (ACR) guidelines for Lyme disease did not use PTLDS in the document, instead it discussed “prolonged symptoms following treatment of Lyme disease” [211].

The PTLDS definition is clinically more narrow than the CLD-PT definition described in this paper [33]. Although both the PTLDS and the CLD-PT definitions address ongoing post-treatment symptoms which last at least 6 months, the PTLDS definition utilizes a limited number of symptoms and more stringent exclusionary criteria. Additionally, PTLDS requires that patients have impairments in their daily functioning. Thus, while a subset of CLD-PT patients would satisfy the PTLDS definition, many would not.

It is also important to note that the PTLDS designation does not speak to the underlying mechanism(s) for ongoing symptoms while the CLD-PT definition specifically requires an ongoing *Bbsl* infection.

8. Limitations

The scientific understanding of chronic Lyme disease is rapidly evolving. While the pathogenic members of the *B. burgdorferi sensu lato* complex are the undisputed cause of Lyme disease, whether there is a role for other pathogens in chronic Lyme disease is unclear. This uncertainty potentially limits the inclusivity of the ILADS CLD definition as the definition does not address non-*Bbsl* pathogens. The CLD-PT subset of the definition requires an ongoing *Bbsl* infection despite antibiotic treatment for Lyme disease; it does not address residual symptoms due to non-*Bbsl* causes such as tissue injury or immune dysregulation. The lack of terminology for these entities is another limitation of the CLD definition.

The narrow focus on ongoing *Bbsl* infection makes the ILADS CLD definition suitable for research purposes (and researchers might use Tables 1 and 2 to identify subjects who may be appropriate for their studies); this definition is not intended to serve as diagnostic criteria. No attempt was made to designate major or minor symptom-based criteria or other diagnostic schemes, which limits the definition’s clinical utility. Chronic Lyme disease, as documented in Tables 1 and 2, has a plethora of clinical presentations and distinguishing this entity from other similarly presenting conditions, both infectious and noninfectious, can be challenging for clinicians. The situation is exacerbated by the

paucity of clinically available direct diagnostic tests that have sufficient sensitivity to reliably identify an active *Bbsl* infection [212,213]. Under these circumstances, clinical manifestations take on increased importance as disease identifiers and clinicians may justifiably arrive at a CLD diagnosis in the absence of direct evidence of an ongoing *Bbsl* infection. In contrast to the ILADS definition, the definition offered by Stricker and Fesler, which is more aptly considered a definition of chronic tick-borne and related diseases, and the Lyme-MSIDS framework may be better suited towards clinical use than research as they encompass the more heterogeneous cohort that is often encountered in clinical practice [27,28]. As such, these two papers could be viewed as complementing the ILADS definition of chronic Lyme disease.

9. Conclusions: Summary and Future Directions

Many patients have ongoing manifestations of Lyme disease for prolonged periods of time. ILADS defines chronic Lyme disease (CLD) as a multisystem illness with a wide range of symptoms and/or signs that are either continuously or intermittently present for a minimum of six months. The illness is the result of an active and ongoing infection by any of several pathogenic members of the *Borrelia burgdorferi sensu lato* complex. The infection has variable latency periods and signs and symptoms may wax, wane and migrate. CLD has two subcategories, CLD, untreated (CLD-U) and CLD, previously treated (CLD-PT). The latter requires that CLD manifestations persist or recur following treatment and are present continuously or in a relapsing/remitting pattern for a duration of six months or more. A systematic search of the literature identified cases meeting either the CLD-U or CLD-PT definition that were accompanied by direct evidence of on-going *Bbsl* infection. These cases documented a wide range of manifestations attributable to this active and ongoing infection. This evidence-based definition of CLD is intended to enhance clinician understanding of this infection and to facilitate future research into the diagnostic and therapeutic options of this oftentimes disabling illness.

Author Contributions: S.S. generated the concept of the work, with contributions from E.L.M. and C.G., S.S., E.L.M., C.G., B.S. and J.B.J. drafted the manuscript. S.S., E.L.M., C.G., B.S., S.P., K.L., J.B.J. and R.B. edited the manuscript. E.L.M. conducted the literature search; S.S., E.L.M., C.G., B.S., S.P., K.L., J.B.J. and R.B. contributed to the review of retrieved papers. E.L.M. created the tables and flow diagram.

Funding: ILADEF-International Lyme and Associated Diseases Educational Foundation has provided funding to support open access for this publication.

Acknowledgments: R.B. Stricker was a member of the working group but withdrew prior to completion of the manuscript.

Conflicts of Interest: J.B.J. is employed by Superior Biologics NY, for which there is no conflict of interest. R.B. has been an expert witness in cases involving Lyme disease. S.S. is presently Chair of the Loudoun County Lyme Commission and past member of Virginia Governor's Task Force on Lyme disease. E.L.M. has been an expert witness in cases involving Lyme disease and served on a subcommittee of the Tick-borne Diseases Working Group. The other authors declare that they have no competing interests.

Abbreviations

<i>Bb</i>	<i>Borrelia burgdorferi</i>
<i>Bbsl</i>	<i>Borrelia burgdorferi sensu lato</i>
CDC	Centers for Disease Control
CLD	Chronic Lyme disease
CLD-U	Chronic Lyme disease, untreated
CLD-PT	Chronic Lyme disease, previously treated
CLD-T	chronic Lyme disease, treated
CSF	cerebrospinal fluid
EM	erythema migrans
DNA	deoxyribonucleic acid
HEENT	head, ears, eyes, nose and throat
IgM	immunoglobulin M
IgG	immunoglobulin G
ILADS	International Lyme and Associated Diseases Society

OSP	outer surface protein
PCR	polymerase chain reaction
PLDS	Post Lyme disease Syndrome
PTLDS	Post-Treatment Lyme disease Syndrome
QoL	Quality of Life
TBD	tick-borne disease

Appendix A

Table A1. *Borrelia burgdorferi sensu lato (Bbsl)* Pathogenicity.

Most Commonly Reported <i>Bbsl</i> Pathogens		
Genospecies	Evidence	Selected References
<i>B. afzelii</i>	Culture	Strle (2006) [37]
<i>B. burgdorferi sensu stricto</i>	Culture	Steere (1984) [34] Nowakowski (2009) [35] Smith (2002) [36]
<i>B. garinii</i>	Culture	Strle (2006) [37]
Less Commonly Reported <i>Bbsl</i> Pathogens		
<i>B. americana</i>	PCR	Clark (2013) [50]
<i>B. andersonii</i>	PCR	Clark (2013) [50]
<i>B. bavariensis</i>	PCR	Markowicz (2015) [48] Tijssse-Klasen (2013) [49]
<i>B. bissettii</i>	PCR	Golovchenko (2016) [45] Rudenko (2008) [46] Rudenko (2009) [47]
<i>B. lusitaniae</i>	PCR	Collares-Pereira (2004) [44]
<i>B. mayonii</i>	PCR	Pritt (2016) [43]
<i>B. spielmanii</i>	Culture & PCR	Maraspin (2006) [38]
	PCR	Fingerle (2008) [39] Földvári (2005) [40]
<i>B. valaisiana</i>	Immunoblot	Ryffel (1999) [41]
<i>B. sp A14S</i>	PCR	Wang (1999) [42]
<i>Bbsl</i> Genospecies Without Established Pathogenicity		
<i>B. californiensis</i>		Postic (2007) [54]
<i>B. carolinensis</i>		Foley (2014) [55]
<i>B. japonica</i>		Rudenko (2011) [51]
<i>B. kurtenbachii</i>		Margos (2010) [56]
<i>B. lanei</i>		Margos (2017) [57]
<i>B. sinica</i>		Rudenko (2011) [51]
<i>B. tanuki</i>		Rudenko (2011) [51]
<i>B. turdi</i>		Rudenko (2011) [51]
<i>B. yangtze</i>		Rudenko (2011) [51]

References

1. Schwartz, A.M.; Hinckley, A.F.; Mead, P.S.; Hook, S.A.; Kugeler, K.J. Surveillance for Lyme Disease-United States, 2008–2015. *MMWR Surveill. Summ.* **2017**, *66*, 1–12. [[CrossRef](#)] [[PubMed](#)]

2. Gray, J.S.; Kirstein, F.; Robertson, J.N.; Stein, J.; Kahl, O. *Borrelia burgdorferi* sensu lato in Ixodes ricinus ticks and rodents in a recreational park in south-western Ireland. *Exp. Appl. Acarol.* **1999**, *23*, 717–729. [[CrossRef](#)] [[PubMed](#)]
3. Nelson, C.A.; Saha, S.; Kugeler, K.J.; Delorey, M.J.; Shankar, M.B.; Hinckley, A.F.; Mead, P.S. Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005–2010. *Emerg. Infect. Dis.* **2015**, *21*, 1625–1631. [[CrossRef](#)] [[PubMed](#)]
4. Logigian, E.L.; Kaplan, R.F.; Steere, A.C. Chronic neurologic manifestations of Lyme disease. *N. Engl. J. Med.* **1990**, *323*, 1438–1444. [[CrossRef](#)]
5. Luft, B.J.; Gorevic, P.D.; Halperin, J.J.; Volkman, D.J.; Dattwyler, R.J. A perspective on the treatment of Lyme borreliosis. *Rev. Infect. Dis.* **1989**, *11*, S1518–S1525. [[CrossRef](#)]
6. Steere, A.C.; Malawista, S.E.; Bartenhagen, N.H.; Spieler, P.N.; Newman, J.H.; Rahn, D.W.; Hutchinson, G.J.; Green, J.; Snyderman, D.R.; Taylor, E. The clinical spectrum and treatment of Lyme disease. *Yale J. Biol. Med.* **1984**, *57*, 453–461.
7. Berger, B.W. Dermatologic manifestations of Lyme disease. *Rev. Infect. Dis.* **1989**, *11*, S1475–S1481. [[CrossRef](#)]
8. Rauer, S.; Kastenbauer, S.; Fingerle, V.; Hunfeld, K.P.; Huppertz, H.I.; Dersch, R. Lyme Neuroborreliosis. *Dtsch. Arztebl. Int.* **2018**, *115*, 751–756. [[CrossRef](#)]
9. Maine Department of Health and Human Services, Center for Disease Control and Prevention, Division of Disease Surveillance. Infectious Disease Epidemiology Program, 2019, Report to Maine Legislature: Lyme and Other Tickborne Illnesses. Available online: <https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/vector-borne/lyme/#reports> (accessed on 26 June 2019).
10. Asch, E.S.; Bujak, D.I.; Weiss, M.; Peterson, M.G.; Weinstein, A. Lyme disease: An infectious and postinfectious syndrome. *J. Rheumatol.* **1994**, *21*, 454–461.
11. Aucott, J.N.; Rebman, A.W.; Crowder, L.A.; Kortte, K.B. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: Is there something here? *Qual. Life Res.* **2013**, *22*, 75–84. [[CrossRef](#)]
12. Cameron, D.J.; Johnson, L.B.; Maloney, E.L. Evidence assessments and guideline recommendations in Lyme disease: The clinical management of known tick bites, erythema migrans rashes and persistent disease. *Expert Rev. Anti Infect. Ther.* **2014**, *12*, 1103–1135. [[CrossRef](#)] [[PubMed](#)]
13. Logigian, E.L.; Kaplan, R.F.; Steere, A.C. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. *J. Infect. Dis.* **1999**, *180*, 377–383. [[CrossRef](#)] [[PubMed](#)]
14. Luft, B.J.; Dattwyler, R.J.; Johnson, R.C.; Luger, S.W.; Bosler, E.M.; Rahn, D.W.; Masters, E.J.; Grunwaldt, E.; Gadgil, S.D. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. *Ann. Intern. Med.* **1996**, *124*, 785–791. [[CrossRef](#)]
15. Shadick, N.A.; Phillips, C.B.; Logigian, E.L.; Steere, A.C.; Kaplan, R.F.; Berardi, V.P.; Duray, P.H.; Larson, M.G.; Wright, E.A.; Ginsburg, K.S.; et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. *Ann. Intern. Med.* **1994**, *121*, 560–567. [[CrossRef](#)]
16. Fallon, B.A.; Keilp, J.G.; Corbera, K.M.; Petkova, E.; Britton, C.B.; Dwyer, E.; Slavov, I.; Cheng, J.; Dobkin, J.; Nelson, D.R.; et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. *Neurology* **2008**, *70*, 992–1003. [[CrossRef](#)] [[PubMed](#)]
17. Klempner, M.S.; Hu, L.T.; Evans, J.; Schmid, C.; Johnson, G.; Trevino, R.; Norton, D.; Levy, L.; Wall, D.; McCall, J.; et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N. Engl. J. Med.* **2001**, *345*, 85–92. [[CrossRef](#)]
18. Krupp, L.B.; Hyman, L.G.; Grimson, R.; Coyle, P.K.; Melville, P.; Ahn, S.; Dattwyler, R.; Chandler, B. Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. *Neurology* **2003**, *60*, 1923–1930. [[CrossRef](#)]
19. Cameron, D. Severity of Lyme disease with persistent symptoms. Insights from a double-blind placebo-controlled clinical trial. *Minerva Med.* **2008**, *99*, 489–496.
20. Johnson, L.; Wilcox, S.; Mankoff, J.; Stricker, R.B. Severity of chronic Lyme disease compared to other chronic conditions: A quality of life survey. *PeerJ* **2014**, *27*, e322. [[CrossRef](#)]
21. Bertrand, E.; Szpak, G.M.; Piłkowska, E.; Habib, N.; Lipczyńska-Lojkowska, W.; Rudnicka, A.; Tylewska-Wierzbanowska, S.; Kulczycki, J. Central nervous system infection caused by *Borrelia burgdorferi*. Clinico-pathological correlation of three post-mortem cases. *Folia Neuropathol.* **1999**, *37*, 43–51. [[PubMed](#)]
22. Cassarino, D.S.; Quezado, M.M.; Ghatak, N.R.; Duray, P.H. Lyme-associated parkinsonism: A neuropathologic case study and review of the literature. *Arch. Pathol. Lab. Med.* **2003**, *127*, 1204–1206. [[PubMed](#)]

23. Liegner, K.B.; Duray, P.; Agricola, M.; Rosenkilde, C.; Yannuzzi, L.; Ziska, M.; Tilton, R.C.; Hulinska, D.; Hubbard, J.; Fallon, B.A. Lyme Disease and the Clinical Spectrum of Antibiotic-Responsive Chronic Meningoencephalomyelitides. *J. Spirochetal Tick Borne Dis.* **1997**, *4*, 61–73.
24. Bransfield, R.C. Suicide and Lyme and associated diseases. *Neuropsychiatr. Dis. Treat.* **2017**, *13*, 1575–1587. [[CrossRef](#)] [[PubMed](#)]
25. Johnson, L.; Aylward, A.; Stricker, R.B. Healthcare access and burden of care for patients with Lyme disease: A large United States survey. *Health Policy* **2011**, *102*, 64–71. [[CrossRef](#)] [[PubMed](#)]
26. Adrion, E.R.; Aucott, J.; Lemke, K.W.; Weiner, J.P. Health care costs, utilization and patterns of care following Lyme disease. *PLoS ONE* **2015**, *10*, e0116767. [[CrossRef](#)]
27. Stricker, R.B.; Fesler, M.F. Chronic Lyme Disease: A Working Case Definition. *Am. J. Infect. Dis.* **2018**, *14*, 1–14. [[CrossRef](#)]
28. Horowitz, R.I.; Freeman, P.R. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2. *Healthcare* **2018**, *6*, 129. [[CrossRef](#)]
29. CSTE Position Statement 11-ID-04. Hepatitis B, Chronic 2012 Case Definition. Available online: <https://wwwn.cdc.gov/nndss/conditions/hepatitis-b-chronic/case-definition/2012/> (accessed on 21 April 2017).
30. Pressler, T.; Bohmova, C.; Conway, S.; Dumcius, S.; Hjelte, L.; Høiby, N.; Kollberg, H.; Tümmler, B.; Vavrova, V. Chronic *Pseudomonas aeruginosa* infection definition: EuroCareCF Working Group report. *J. Cystic Fibrosis* **2011**, *10*, S75–S78. [[CrossRef](#)]
31. Krause, P.J.; Telford, S.R., III; Spielman, A.; Sikand, V.; Ryan, R.; Christianson, D.; Burke, G.; Brassard, P.; Pollack, R.; Peck, J.; et al. Concurrent Lyme disease and babesiosis: Evidence for increased severity and duration of illness. *JAMA* **1996**, *275*, 1657–1660. [[CrossRef](#)]
32. Thompson, C.; Spielman, A.; Krause, P.J. Coinfecting deer-associated zoonoses: Lyme disease, babesiosis, and ehrlichiosis. *Clin. Infect. Dis.* **2001**, *33*, 676–685. [[CrossRef](#)]
33. Aucott, J.N.; Crowder, L.A.; Kortte, K.B. Development of a foundation for a case definition of post-treatment Lyme disease syndrome. *Int. J. Infect. Dis.* **2013**, *17*, e443–e449. [[CrossRef](#)] [[PubMed](#)]
34. Steere, A.C.; Grodzicki, R.L.; Craft, J.E.; Shrestha, M.; Kornblatt, A.N.; Malawista, S.E. Recovery of Lyme disease spirochetes from patients. *Yale J. Biol. Med.* **1984**, *57*, 557–560. [[PubMed](#)]
35. Nowakowski, J.; McKenna, D.; Nadelman, R.B.; Bittker, S.; Cooper, D.; Pavia, C.; Holmgren, D.; Visintainer, P.; Wormser, G.P. Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. *Clin. Infect. Dis.* **2009**, *49*, 1733–1735. [[CrossRef](#)] [[PubMed](#)]
36. Smith, R.P.; Schoen, R.T.; Rahn, D.W.; Sikand, V.K.; Nowakowski, J.; Parenti, D.L.; Holman, M.S.; Persing, D.H.; Steere, A.C. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. *Ann. Intern. Med.* **2002**, *136*, 421–428. [[CrossRef](#)] [[PubMed](#)]
37. Strle, F.; Ruzić-Sabljić, E.; Cimperman, J.; Lotric-Furlan, S.; Maraspin, V. Comparison of findings for patients with *Borrelia garinii* and *Borrelia afzelii* isolated from cerebrospinal fluid. *Clin. Infect. Dis.* **2006**, *43*, 704–710. [[CrossRef](#)]
38. Maraspin, V.; Ruzic-Sabljić, E.; Strle, F. Lyme borreliosis and *Borrelia spielmanii*. *Emerg. Infect. Dis.* **2006**, *12*, 1177. [[CrossRef](#)]
39. Fingerle, V.; Schulte-Spechtel, U.C.; Ruzic-Sabljić, E.; Leonhard, S.; Hofmann, H.; Weber, K.; Pfister, K.; Strle, F.; Wilske, B. Epidemiological aspects and molecular characterization of *Borrelia burgdorferi* s.l. from southern Germany with special respect to the new species *Borrelia spielmanii* sp. nov. *Int. J. Med. Microbiol.* **2008**, *298*, 279–290.
40. Földvári, G.; Farkas, R.; Lakos, A. *Borrelia spielmanii* erythema migrans, Hungary. *Emerg. Infect. Dis.* **2005**, *11*, 1794–1795. [[CrossRef](#)]
41. Ryffel, K.; Péter, O.; Rutti, B.; Suard, A.; Dayer, E. Scored antibody reactivity determined by immunoblotting shows an association between clinical manifestations and presence of *Borrelia burgdorferi* sensu stricto, *B. garinii*, *B. afzelii*, and *B. valaisiana* in humans. *J. Clin. Microbiol.* **1999**, *37*, 4086–4092.
42. Wang, G.; van Dam, A.P.; Schwartz, I.; Dankert, J. Molecular typing of *Borrelia burgdorferi* sensu lato: Taxonomic, epidemiological, and clinical implications. *Clin. Microbiol. Rev.* **1999**, *2*, 633–653. [[CrossRef](#)]
43. Pritt, B.S.; Respcio-Kingry, L.B.; Sloan, L.M.; Schriefer, M.E.; Replogle, A.J.; Bjork, J.; Liu, G.; Kingry, L.C.; Mead, P.S.; Neitzel, D.F.; et al. *Borrelia mayonii* sp. nov. a member of the *Borrelia burgdorferi* sensu lato complex, detected in patients and ticks in the upper midwestern United States. *Int. J. Syst. Evol. Microbiol.* **2016**, *66*, 4878–4880. [[CrossRef](#)] [[PubMed](#)]

44. Collares-Pereira, M.; Couceiro, S.; Franca, I.; Kurtenbach, K.; Schafer, S.M.; Vitorino, L.; Goncalves, L.; Baptista, S.; Vieira, M.L.; Cunha, C. First isolation of *Borrelia lusitaniae* from a human patient. *J. Clin. Microbiol.* **2004**, *42*, 1316–1318. [[CrossRef](#)] [[PubMed](#)]
45. Golovchenko, M.; Vancová, M.; Clark, K.; Oliver, J.H.; Grubhoffer, L.; Rudenko, N. A divergent spirochete strain isolated from a resident of the southeastern United States was identified by multilocus sequence typing as *Borrelia bissettii*. *Parasites Vectors* **2016**, *9*, 68. [[CrossRef](#)] [[PubMed](#)]
46. Rudenko, N.; Golovchenko, M.; Mokráček, A.; Piskunová, N.; Ruzek, D.; Mallatová, N.; Grubhoffer, L. Detection of *Borrelia bissettii* in cardiac valve tissue of a patient with endocarditis and aortic valve stenosis in the Czech Republic. *J. Clin. Microbiol.* **2008**, *46*, 3540–3543. [[CrossRef](#)] [[PubMed](#)]
47. Rudenko, N.; Golovchenko, M.; Ruzek, D.; Piskunova, N.; Mallatová, N.; Grubhoffer, L. Molecular detection of *Borrelia bissettii* DNA in serum samples from patients in the Czech Republic with suspected borreliosis. *FEMS Microbiol. Lett.* **2009**, *292*, 274–281. [[CrossRef](#)] [[PubMed](#)]
48. Markowicz, M.; Ladstätter, S.; Schotta, A.M.; Reiter, M.; Pomberger, G.; Stanek, G. Oligoarthritis caused by *Borrelia bavariensis*, Austria, 2014. *Emerg. Infect. Dis.* **2015**, *21*, 1052–1054. [[CrossRef](#)] [[PubMed](#)]
49. Tjisse-Klasen, E.; Pandak, N.; Hengeveld, P.; Takumi, K.; Koopmans, M.P.; Sprong, H. Ability to cause erythema migrans differs between *Borrelia burgdorferi sensu lato* isolates. *Parasites Vectors* **2013**, *6*, 23. [[CrossRef](#)]
50. Clark, K.L.; Leydet, B.; Hartman, S. Lyme borreliosis in human patients in Florida and Georgia, USA. *Int. J. Med. Sci.* **2013**, *10*, 915–931. [[CrossRef](#)]
51. Rudenko, N.; Golovchenko, M.; Grubhoffer, L.; Oliver, J.H., Jr. Updates on *Borrelia burgdorferi sensu lato* complex with respect to public health. *Ticks Tick Borne Dis.* **2011**, *2*, 123–128. [[CrossRef](#)]
52. Krause, P.J.; Narasimhan, S.; Wormser, G.P.; Rollend, L.; Fikrig, E.; Lepore, T.; Barbour, A.; Fish, D. Human *Borrelia miyamotoi* infection in the United States. *N. Engl. J. Med.* **2013**, *368*, 291. [[CrossRef](#)]
53. Daniel, M.; Rudenko, N.; Golovchenko, M.; Danielová, V.; Fialová, A.; Kříž, B.; Malý, M. The occurrence of *Ixodes ricinus* ticks and important tick-borne pathogens in areas with high tick-borne encephalitis prevalence in different altitudinal levels of the Czech Republic Part II. *Ixodes ricinus* ticks and genospecies of *Borrelia burgdorferi sensu lato* complex. *Epidemiol. Mikrobiol. Imunol.* **2016**, *65*, 182–192. [[PubMed](#)]
54. Postic, D.; Garnier, M.; Baranton, G. Multilocus sequence analysis of atypical *Borrelia burgdorferi sensu lato* isolates—description of *Borrelia californiensis* sp. nov and genomospecies 1 and 2. *Int. J. Med. Microbiol.* **2007**, *297*, 263–271. [[CrossRef](#)] [[PubMed](#)]
55. Foley, J.; Ott-Conn, C.; Worth, J.; Poulsen, A.; Clifford, D. An *Ixodes minor* and *Borrelia carolinensis* enzootic cycle involving a critically endangered Mojave Desert rodent. *Ecol. Evol.* **2014**, *4*, 576–581. [[CrossRef](#)] [[PubMed](#)]
56. Margos, G.; Hojgaard, A.; Lane, R.S.; Cornet, M.; Fingerle, V.; Rudenko, N.; Ogden, N.; Aanensen, D.M.; Fish, D.; Piesman, J. Multilocus sequence analysis of *Borrelia bissettii* strains from North America reveals a new *Borrelia* species, *Borrelia kurtenbachii*. *Ticks Tick Borne Dis.* **2010**, *1*, 151–158. [[CrossRef](#)] [[PubMed](#)]
57. Margos, G.; Fedorova, N.; Kleinjan, J.E.; Hartberger, C.; Schwan, T.G.; Sing, A.; Fingerle, V. *Borrelia lanei* sp. nov. extends the diversity of *Borrelia* species in California. *Int. J. Syst. Evol. Microbiol.* **2017**, *67*, 3872–3876. [[CrossRef](#)]
58. Caulfield, A.J.; Pritt, B.S. Lyme Disease Coinfections in the United States. *Clin. Lab. Med.* **2015**, *35*, 827–846. [[CrossRef](#)]
59. Preac Mursic, V.; Marget, W.; Busch, U.; Pleterski Rigler, D.; Hagl, S. Kill kinetics of *Borrelia burgdorferi* and bacterial findings in relation to the treatment of Lyme borreliosis. *Infection* **1996**, *24*, 9–16. [[CrossRef](#)]
60. Stanek, G.; Reiter, M. The expanding Lyme *Borrelia* complex—clinical significance of genomic species? *Clin. Microbiol. Infect.* **2011**, *17*, 487–493. [[CrossRef](#)]
61. Carpi, G.; Kitchen, A.; Kim, H.L.; Ratan, A.; Drautz-Moses, D.I.; McGraw, J.J.; Kazimirova, M.; Rizzoli, A.; Schuster, S.C. Mitogenomes reveal diversity of the European Lyme borreliosis vector *Ixodes ricinus* in Italy. *Mol. Phylogenet Evol.* **2016**, *101*, 194–202. [[CrossRef](#)]
62. Korenberg, E.I.; Nefedova, V.V.; Romanenko, V.N.; Gorelova, N.B. The tick *Ixodes pavlovskyi* as a host of spirochetes pathogenic for humans and its possible role in the epizootiology and epidemiology of borrelioses. *Vector Borne Zoonotic Dis.* **2010**, *10*, 453–458. [[CrossRef](#)]
63. Shpynov, S. *Ixodes persulcatus*, a major vector of Alphaproteobacteria in Russia. *Ticks Tick Borne Dis.* **2012**, *3*, 305–307. [[CrossRef](#)] [[PubMed](#)]
64. Schulze, T.L.; Taylor, R.C.; Taylor, G.C.; Bosler, E.M. Lyme disease: A proposed ecological index to assess areas of risk in the northeastern United States. *Am. J. Public Health.* **1991**, *81*, 714–718. [[CrossRef](#)] [[PubMed](#)]

65. Lane, R.S.; Steinlein, D.B.; Mun, J. Human Behaviors elevating exposure to *Ixodes pacificus* (Acari: Ixodidae) nymphs and their associated bacterial zoonotic agents in a hardwood forest. *J. Med. Entomol.* **2004**, *41*, 239–248. [CrossRef] [PubMed]
66. Dubska, L.; Literak, I.; Kocianova, E.; Taragelova, V.; Sychra, O. Differential role of passerine birds in distribution of *Borrelia* spirochetes, based on data from ticks collected from birds during the postbreeding migration period in Central Europe. *Appl. Environ. Microbiol.* **2009**, *75*, 596–602. [CrossRef] [PubMed]
67. Hubálek, Z. An annotated checklist of pathogenic microorganisms associated with migratory birds. *J. Wildl. Dis.* **2004**, *40*, 639–659. [CrossRef] [PubMed]
68. Scott, J.D.; Anderson, J.F.; Durden, L.A. Widespread Dispersal of *Borrelia burgdorferi*-infected ticks collected from songbirds across Canada. *J. Parasitol.* **2012**, *98*, 49–59. [CrossRef]
69. Eisen, R.J.; Eisen, L.; Beard, C.B. County-Scale Distribution of *Ixodes scapularis* and *Ixodes pacificus* (Acari: Ixodidae) in the Continental United States. *J. Med. Entomol.* **2016**, *53*, 349–386. [CrossRef]
70. Lindgren, E.; Thomas, G.; Jaenson, T. Lyme Borreliosis in Europe: Influences of Climate and Climate Change, Epidemiology, Ecology and Adaptation Measures. World Health Organization Publication. Available online: <http://www.euro.who.int/en/publications/abstracts/lyme-borreliosis-in-europe-influences-of-climate-and-climate-change-epidemiology-ecology-and-adaptation-measures/> (accessed on 30 May 2019).
71. Coyle, P.K.; Schutzer, S.E.; Deng, Z.; Krupp, L.B.; Belman, A.L.; Benach, J.L.; Luft, B.J. Detection of *Borrelia burgdorferi*-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. *Neurology* **1995**, *45*, 2010–2015. [CrossRef]
72. Mikkila, H.O.; Seppala, I.J.; Viljanen, M.K.; Peltomaa, M.P.; Karma, A. The expanding clinical spectrum of ocular Lyme borreliosis. *Ophthalmology* **2000**, *107*, 581–587. [CrossRef]
73. Nocton, J.J.; Dressler, F.; Rutledge, B.J.; Rys, P.N.; Persing, D.H.; Steere, A.C. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. *N. Engl. J. Med.* **1994**, *330*, 229–234. [CrossRef]
74. Nocton, J.J.; Bloom, B.J.; Rutledge, B.J.; Persing, D.H.; Logigian, E.L.; Schmid, C.H.; Steere, A.C. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. *J. Infect. Dis.* **1996**, *174*, 623–627. [CrossRef] [PubMed]
75. Oksi, J.; Kalimo, H.; Marttila, R.J.; Marjamäki, M.; Sonninen, P.; Nikoskelainen, J.; Viljanen, M.K. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature. *Brain* **1996**, *119*, 2143–2154. [CrossRef] [PubMed]
76. Preac-Mursic, V.; Pfister, H.W.; Spiegel, H.; Burk, R.; Wilske, B.; Reinhardt, S.; Böhmer, R. First isolation of *Borrelia burgdorferi* from an iris biopsy. *J. Clin. Neuro Ophthalmol.* **1993**, *13*, 155–161.
77. Aberer, E.; Kersten, A.; Klade, H.; Poitschek, C.; Jurecka, W. Heterogeneity of *Borrelia burgdorferi* in the skin. *Am. J. Dermatopathol.* **1996**, *18*, 571–579. [CrossRef]
78. Chmielewski, T.; Tylewska-Wierzhanowska, S. Inhibition of fibroblast apoptosis by *Borrelia afzelii*, *Coxiella burnetii* and *Bartonella henselae*. *Pol. J. Microbiol.* **2011**, *60*, 269–272. [CrossRef]
79. De Koning, J.; Hoogenkamp-Korstanje, J.A.; van der Linde, M.R.; Crijns, H.J. Demonstration of spirochetes in cardiac biopsies of patients with Lyme disease. *J. Infect. Dis.* **1989**, *160*, 150–153. [CrossRef] [PubMed]
80. Dorward, D.W.; Fischer, E.R.; Brooks, D.M. Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme disease. *Clin. Infect. Dis.* **1991**, *25*, S2–S8. [CrossRef]
81. Georgilis, K.; Peacocke, M.; Klempner, M.S. Fibroblasts protect the Lyme disease spirochete, *Borrelia burgdorferi*, from ceftriaxone in vitro. *J. Infect. Dis.* **1992**, *166*, 440–444. [CrossRef] [PubMed]
82. Girschick, H.J.; Huppertz, H.I.; Rüssmann, H.; Krenn, V.; Karch, H. Intracellular persistence of *Borrelia burgdorferi* in human synovial cells. *Rheumatol. Int.* **1996**, *16*, 125–132. [CrossRef]
83. Häupl, T.; Hahn, G.; Rittig, M.; Krause, A.; Schoerner, C.; Schonherr, U.; Kalden, J.R.; Burmester, G.R. Persistence of *Borrelia burgdorferi* in ligamentous tissue from a patient with chronic Lyme borreliosis. *Arthritis Rheum.* **1993**, *36*, 1621–1626. [CrossRef]
84. Klempner, M.S.; Noring, R.; Rogers, R.A. Invasion of human skin fibroblasts by the Lyme disease spirochete, *Borrelia burgdorferi*. *J. Infect. Dis.* **1993**, *167*, 1074–1081. [CrossRef] [PubMed]
85. Livengood, J.A.; Gilmore, R.D. Invasion of human neuronal and glial cells by an infectious strain of *Borrelia burgdorferi*. *Microbes Infect.* **2006**, *8*, 2832–2840. [CrossRef] [PubMed]
86. Ma, Y.; Sturrock, A.; Weis, J.J. Intracellular localization of *Borrelia burgdorferi* within human endothelial cells. *Infect. Immun.* **1991**, *59*, 671–678. [PubMed]

87. Nanagara, R.; Duray, P.H.; Schumacher, H.R. Ultrastructural demonstration of spirochetal antigens in synovial fluid and synovial membrane in chronic Lyme disease: Possible factors contributing to persistence of organisms. *Hum. Pathol.* **1996**, *27*, 1025–1034. [[CrossRef](#)]
88. Stanek, G.; Klein, J.; Bittner, R.; Glogar, D. Isolation of *Borrelia burgdorferi* from the myocardium of a patient with longstanding cardiomyopathy. *N. Engl. J. Med.* **1990**, *322*, 249–252. [[CrossRef](#)]
89. Valesova, M.; Trnavský, K.; Hulínská, D.; Alusík, S.; Janousek, J.; Jirous, J. Detection of *Borrelia* in the synovial tissue from a patient with Lyme borreliosis by electron microscopy. *J. Rheumatol.* **1989**, *16*, 1502–1505.
90. Duray, P.H.; Steere, A.C. Clinical pathologic correlations of Lyme disease by stage. *Ann. N. Y. Acad. Sci.* **1988**, *539*, 65–79. [[CrossRef](#)]
91. Halperin, J.J.; Volkman, D.; Wu, P. Central nervous system abnormalities in Lyme neuroborreliosis. *Neurology* **1991**, *41*, 1571–1582. [[CrossRef](#)]
92. Halperin, J.J.; Little, B.W.; Coyle, P.K.; Dattwyler, R.J. Lyme disease: Cause of a treatable peripheral neuropathy. *Neurology* **1987**, *37*, 1700–1706. [[CrossRef](#)]
93. Broderick, J.P.; Sandok, B.A.; Mertz, L.E. Focal encephalitis in a young woman 6 years after the onset of Lyme disease: Tertiary Lyme disease? *Mayo Clin. Proc.* **1987**, *62*, 313–316. [[CrossRef](#)]
94. Coyle, P.K. Neurologic aspects of Lyme disease. *Med. Clin. N. Am.* **2002**, *86*, 261–284. [[CrossRef](#)]
95. Fallon, B.A.; Schwartzberg, M.; Bransfield, R.; Zimmerman, B.; Scotti, A.; Weber, C.A.; Liebowitz, M.R. Late-Stage Neuropsychiatric Lyme Borreliosis: Differential Diagnosis and Treatment. *Psychosomatics* **1995**, *36*, 295–300. [[CrossRef](#)]
96. Fallon, B.A.; Nields, J.A. Lyme Disease: A Neuropsychiatric Illness. *Am. J. Psychiatry* **1994**, *151*, 1571–1583. [[PubMed](#)]
97. Reik, L.; Steere, A.C.; Bartenhagen, N.H.; Shope, R.E.; Malawista, S.E. Neurologic abnormalities of Lyme disease. *Medicine* **1979**, *58*, 281–294. [[CrossRef](#)] [[PubMed](#)]
98. Wormser, G.P.; Dattwyler, R.J.; Shapiro, E.D.; Halperin, J.J.; Steere, A.C.; Klemmner, M.S.; Krause, P.J.; Bakken, J.S.; Strle, F.; Stanek, G.; et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **2006**, *43*, 1089–1134. [[CrossRef](#)] [[PubMed](#)]
99. Kanjwal, K.; Karabin, B.; Kanjwal, Y.; Grubb, B.P. Postural orthostatic tachycardia syndrome following Lyme disease. *Cardiol. J.* **2011**, *18*, 63–66. [[PubMed](#)]
100. Dinerman, H.; Steere, A.C. Lyme disease associated with fibromyalgia. *Ann. Intern. Med.* **1992**, *117*, 281–285. [[CrossRef](#)] [[PubMed](#)]
101. Bransfield, R.C. The psychoimmunology of lyme/tick-borne diseases and its association with neuropsychiatric symptoms. *Open Neurol. J.* **2012**, *6*, 88–93. [[CrossRef](#)] [[PubMed](#)]
102. Nicolson, G.L.; Settineri, R.; Ellithorpe, R. Lipid Replacement Therapy with a Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces Fatigue in Intractable Chronic Fatiguing Illnesses and Chronic Lyme Disease Patients. *Int. J. Clin. Med.* **2012**, *3*, 163–170. [[CrossRef](#)]
103. Jutras, B.L.; Savage, C.R.; Arnold, W.K.; Lethbridge, K.G.; Carroll, D.W.; Tilly, K.; Bestor, A.; Zhu, H.; Seshu, J.; Zückert, W.R.; et al. *Borrelia burgdorferi* peptidoglycan is a persistent antigen in patients with Lyme arthritis. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 13498–13507. [[CrossRef](#)]
104. Bockenstedt, L.K.; Gonzalez, D.G.; Haberman, A.M.; Belperron, A.A. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. *J. Clin. Investig.* **2012**, *122*, 2652–2660. [[CrossRef](#)]
105. Arvikar, S.L.; Crowley, J.T.; Sulka, K.B.; Steere, A.C. Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease. *Arthritis Rheumatol.* **2017**, *69*, 194–202. [[CrossRef](#)] [[PubMed](#)]
106. Maccallini, P.; Bonin, S.; Trevisan, G. Autoimmunity against a glycolytic enzyme as a possible cause for persistent symptoms in Lyme disease. *Med. Hypotheses* **2018**, *110*, 1–8. [[CrossRef](#)] [[PubMed](#)]
107. Fallon, B.A.; Levin, E.S.; Schweitzer, P.J.; Hardesty, D. Inflammation and central nervous system Lyme disease. *Neurobiol. Dis.* **2010**, *37*, 534–541. [[CrossRef](#)] [[PubMed](#)]
108. Strle, K.; Sulka, K.B.; Pianta, A.; Crowley, J.T.; Arvikar, S.L.; Anselmo, A.; Sadreyev, R.; Steere, A.C. T-Helper 17 Cell Cytokine Responses in Lyme Disease Correlate with *Borrelia burgdorferi* Antibodies During Early Infection and With Autoantibodies Late in the Illness in Patients With Antibiotic-Refractory Lyme Arthritis. *Clin. Infect. Dis.* **2017**, *64*, 930–938. [[CrossRef](#)] [[PubMed](#)]

109. Donta, S.T. Issues in the diagnosis and treatment of Lyme disease. *Open Neurol. J.* **2012**, *6*, 140–145. [[CrossRef](#)] [[PubMed](#)]
110. Delong, A.K.; Blossom, B.; Maloney, E.L.; Phillips, S.E. Antibiotic retreatment of Lyme disease in patients with persistent symptoms: A biostatistical review of randomized, placebo-controlled, clinical trials. *Contemp. Clin. Trials* **2012**, *33*, 1132–1142. [[CrossRef](#)]
111. Schmidli, J.; Hunziker, T.; Moesli, P.; Schaad, U.B. Cultivation of *Borrelia burgdorferi* from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. *J. Infect. Dis.* **1988**, *158*, 905–906. [[CrossRef](#)] [[PubMed](#)]
112. Kirsch, M.; Ruben, F.L.; Steere, A.C.; Duray, P.H.; Norden, C.W.; Winkelstein, A. Fatal adult respiratory distress syndrome in a patient with Lyme disease. *JAMA* **1988**, *259*, 2737–2739. [[CrossRef](#)] [[PubMed](#)]
113. Preac-Mursic, V.; Weber, K.; Pfister, H.W.; Wilske, B.; Gross, B.; Baumann, A.; Prokop, J. Survival of *Borrelia burgdorferi* in antibioticly treated patients with Lyme borreliosis. *Infection* **1989**, *17*, 355–359. [[CrossRef](#)]
114. Pfister, H.W.; Preac-Mursic, V.; Wilske, B.; Schielke, E.; Sorgel, F.; Einhaupl, K.M. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. *J. Infect. Dis.* **1991**, *163*, 311–318. [[CrossRef](#)] [[PubMed](#)]
115. Liegner, K.B.; Shapiro, J.R.; Ramsay, D.; Halperin, A.; Hogrefe, W.; Kong, L. Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting *Borrelia burgdorferi* infection. *J. Am. Acad. Dermatol.* **1993**, *28*, 312–314. [[CrossRef](#)]
116. Strle, F.; Preac-Mursic, V.; Cimperman, J.; Ruzic, E.; Maraspin, V.; Jereb, M. Azithromycin versus doxycycline for treatment of erythema migrans: Clinical and microbiological findings. *Infection* **1993**, *21*, 83–88. [[CrossRef](#)] [[PubMed](#)]
117. Weber, K.; Wilske, B.; Preac-Mursic, V.; Thurmayr, R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. *Infection* **1993**, *21*, 367–372. [[CrossRef](#)]
118. Battafarano, D.F.; Combs, J.A.; Enzenauer, R.J.; Fitzpatrick, J.E. Chronic septic arthritis caused by *Borrelia burgdorferi*. *Clin. Orthop. Relat. Res.* **1993**, *297*, 238–241.
119. Chancellor, M.B.; McGinnis, D.E.; Shenot, P.J.; Kiilholma, P.; Hirsch, I.H. Urinary dysfunction in Lyme disease. *J. Urol.* **1993**, *149*, 26–30. [[CrossRef](#)]
120. Bradley, J.F.; Johnson, R.C.; Goodman, J.L. The persistence of spirochetal nucleic acids in active Lyme arthritis. *Ann. Intern. Med.* **1994**, *120*, 487–489. [[CrossRef](#)]
121. Lawrence, C.; Lipton, R.B.; Lowy, F.D.; Coyle, P.K. Seronegative chronic relapsing neuroborreliosis. *Eur. Neurol.* **1995**, *35*, 113–117. [[CrossRef](#)]
122. Strle, F.; Maraspin, V.; Lotric-Furlan, S.; Ruzic-Sabljić, E.; Cimperman, J. Azithromycin and doxycycline for treatment of *Borrelia* culture-positive erythema migrans. *Infection* **1996**, *24*, 64–68. [[CrossRef](#)]
123. Oksi, J.; Nikoskelainen, J.; Viljanen, M.K. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. *Eur. J. Clin. Microbiol. Infect. Dis.* **1998**, *17*, 715–719. [[CrossRef](#)]
124. Priem, S.; Burmester, G.R.; Kamradt, T.; Wolbart, K.; Rittig, M.G.; Krause, A. Detection of *Borrelia burgdorferi* by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. *Ann. Rheum. Dis.* **1998**, *57*, 118–121. [[CrossRef](#)] [[PubMed](#)]
125. Hudson, B.J.; Stewart, M.; Lennox, V.A.; Fukunaga, M.; Yabuki, M.; Macorison, H.; Kitchener-Smith, J. Culture-positive Lyme borreliosis. *Med. J. Aust.* **1998**, *168*, 500–502. [[CrossRef](#)] [[PubMed](#)]
126. Oksi, J.; Marjamaki, M.; Nikoskelainen, J.; Viljanen, M.K. *Borrelia burgdorferi* detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. *Ann. Med.* **1999**, *31*, 225–232. [[CrossRef](#)] [[PubMed](#)]
127. Breier, F.; Khanakah, G.; Stanek, G.; Kunz, G.; Aberer, E.; Schmidt, B.; Tappeiner, G. Isolation and polymerase chain reaction typing of *Borrelia afzelii* from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. *Br. J. Dermatol.* **2001**, *144*, 387–392. [[CrossRef](#)] [[PubMed](#)]
128. Hunfeld, K.P.; Ruzic-Sabljić, E.; Norris, D.E.; Kraiczky, P.; Strle, F. In vitro susceptibility testing of *Borrelia burgdorferi* sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. *Antimicrob. Agents Chemother.* **2005**, *49*, 1294–1301. [[CrossRef](#)]
129. Marques, A.; Telford, S.R.; Turk, S.P.; Chung, E.; Williams, C.; Dardick, K.; Krause, P.J.; Brandeburg, C.; Crowder, C.D.; Carolan, H.E.; et al. Xenodiagnosis to detect *Borrelia burgdorferi* infection: A first-in-human study. *Clin. Infect. Dis.* **2014**, *58*, 937–945. [[CrossRef](#)]
130. Embers, M.E.; Barthold, S.W.; Borda, J.T.; Bowers, L.; Doyle, L.; Hodzic, E.; Jacobs, M.B.; Hasenkampf, N.R.; Martin, D.S.; Narasimhan, S.; et al. Persistence of *Borrelia burgdorferi* in Rhesus Macaques following antibiotic treatment of disseminated infection. *PLoS ONE* **2012**, *7*, e29914. [[CrossRef](#)]

131. Hodzic, E.; Feng, S.; Holden, K.; Freet, K.J.; Barthold, S.W. Persistence of *Borrelia burgdorferi* following antibiotic treatment in mice. *Antimicrob. Agents Chemother.* **2008**, *52*, 1728–1736. [[CrossRef](#)]
132. Barthold, S.W.; Hodzic, E.; Imai, D.M.; Feng, S.; Yang, X.; Luft, B.L. Ineffectiveness of tigecycline against persistent *Borrelia burgdorferi*. *Antimicrob. Agents Chemother.* **2010**, *54*, 643–651. [[CrossRef](#)]
133. Straubinger, R.K.; Summers, B.A.; Chang, Y.F.; Appel, M.J. Persistence of *Borrelia burgdorferi* in experimentally infected dogs after antibiotic treatment. *J. Clin. Microbiol.* **1997**, *35*, 111–116.
134. Embers, M.E.; Hasenkampf, N.R.; Jacobs, M.B.; Tardo, A.C.; Doyle-Meyers, L.A.; Philipp, M.T.; Hodzic, E. Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to *Borrelia burgdorferi* by tick feeding. *PLoS ONE* **2017**, *12*, e0189071. [[CrossRef](#)] [[PubMed](#)]
135. Rudenko, N.; Golovchenko, M.; Kybiceva, K.; Vancova, M. Metamorphoses of Lyme disease spirochetes: Phenomenon of *Borrelia* persists. *Parasites Vectors* **2019**, *12*, 1–10. [[CrossRef](#)] [[PubMed](#)]
136. Tager, F.A.; Fallon, B.A.; Keilp, J.; Rissenberg, M.; Jones, C.R.; Liebowitz, M.R. A Controlled Study of Cognitive Deficits in Children with Chronic Lyme Disease. *J. Neuropsychiatry Clin. Neurosci.* **2001**, *13*, 500–507. [[CrossRef](#)] [[PubMed](#)]
137. Pfister, H.W.; Preac-Mursic, V.; Wilske, B.; Einhäupl, K.M.; Weinberger, K. Latent Lyme neuroborreliosis: Presence of *Borrelia burgdorferi* in the cerebrospinal fluid without concurrent inflammatory signs. *Neurology* **1989**, *39*, 1118. [[CrossRef](#)]
138. Oksi, J.; Nikoskelainen, J.; Hiekkänen, H.; Lauhio, A.; Peltomaa, M.; Pitkäranta, A.; Nyman, D.; Granlund, H.; Carlsson, S.A.; Seppälä, I.; et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: A double-blind, randomized, placebo-controlled, multicenter clinical study. *Eur. J. Clin. Microbiol. Infect. Dis.* **2007**, *26*, 571–581. [[CrossRef](#)]
139. Fraser, D.D.; Kong, L.I.; Miller, F.W. Molecular detection of persistent *Borrelia burgdorferi* in a man with dermatomyositis. *Clin. Exp. Rheumatol.* **1992**, *10*, 387–390.
140. Frey, M.; Jaulhac, B.; Piemont, Y.; Marcellin, L.; Boohs, P.M.; Vautravers, P.; Jessel, M.; Kuntz, J.L.; Monteil, H.; Sibia, J. Detection of *Borrelia burgdorferi* DNA in muscle of patients with chronic myalgia related to Lyme disease. *Am. J. Med.* **1998**, *104*, 591–594. [[CrossRef](#)]
141. Brouqui, P.; Badiaga, S.; Raoult, D. Eucaryotic cells protect *Borrelia burgdorferi* from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. *Antimicrob. Agents Chemother.* **1996**, *40*, 1552–1554. [[CrossRef](#)]
142. Hodzic, E.; Feng, S.; Freet, K.J.; Barthold, S.W. *Borrelia burgdorferi* population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. *Infect. Immun.* **2003**, *71*, 5042–5055. [[CrossRef](#)]
143. Embers, M.E.; Ramamoorthy, R.; Philipp, M.T. Survival strategies of *Borrelia burgdorferi*, the etiologic agent of Lyme disease. *Microbes Infect.* **2004**, *6*, 312–318. [[CrossRef](#)]
144. Cabello, F.C.; Godfrey, H.P.; Newman, S.A. Hidden in plain sight: *Borrelia burgdorferi* and the extracellular matrix. *Trends Microbiol.* **2007**, *15*, 350–354. [[CrossRef](#)] [[PubMed](#)]
145. Szczepanski, A.; Benach, J.L. Lyme borreliosis: Host responses to *Borrelia burgdorferi*. *Microbiol. Mol. Biol. Rev.* **1991**, *55*, 21–34.
146. Sapi, E.; Bastian, S.L.; Mpoy, C.M.; Scott, S.; Rattelle, A.; Pabbati, N.; Poruri, A.; Burugu, D.; Theophilus, P.A.; Pham, T.V.; et al. Characterization of biofilm formation by *Borrelia burgdorferi* in vitro. *PLoS ONE* **2012**, *7*, 1–11. [[CrossRef](#)] [[PubMed](#)]
147. Sapi, E.; Balasubramanian, K.; Poruri, A.; Maghsoudlou, J.S.; Socarras, K.M.; Timmaraju, A.V.; Filush, K.R.; Gupta, K.; Shaikh, S.; Theophilus, P.A.; et al. Evidence of in vivo existence of *Borrelia* biofilm in Borreliac lymphocytomas. *Eur. J. Microbiol. Immunol.* **2016**, *6*, 9–24. [[CrossRef](#)]
148. Sapi, E.; Kasliwala, R.S.; Ismail, H.; Torres, J.P.; Oldakowski, M.; Markland, S.; Gaur, G.; Melillo, A.; Eisendle, K.; Liegner, K.B.; et al. The Long-Term Persistence of *Borrelia burgdorferi* Antigens and DNA in the Tissues of a Patient with Lyme Disease. *Antibiotics* **2019**, *8*, 183. [[CrossRef](#)]
149. Zhang, J.R.; Hardham, J.M.; Barbour, A.G.; Norris, S.J. Antigenic Variation in Lyme Disease *Borreliae* by Promiscuous Recombination of VMP-like Sequence Cassettes. *Cell* **1997**, *89*, 275–285. [[CrossRef](#)]
150. Coutte, L.; Botkin, D.J.; Gao, L.; Norris, S.J. Detailed Analysis of Sequence Changes Occurring during vlsE Antigenic Variation in the Mouse Model of *Borrelia burgdorferi* Infection. *PLoS Pathog.* **2009**, *5*, e1000293. [[CrossRef](#)]
151. Liang, F.T.; Jacobs, M.B.; Bowers, L.C.; Philipp, M.T. An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. *J. Exp. Med.* **2002**, *195*, 415–422. [[CrossRef](#)]

152. Barbour, A.G.; Restrepo, B.I. Antigenic variation in vector-borne pathogens. *Emerg. Infect. Dis.* **2000**, *6*, 449–457. [[CrossRef](#)]
153. Schwan, T.G.; Piesman, J. Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, *Borrelia burgdorferi*, during the chain of infection in ticks and mice. *J. Clin. Microbiol.* **2000**, *38*, 382–388.
154. Mursic, V.P.; Wannier, G.; Reinhardt, S.; Wilske, B.; Busch, U.; Marget, W. Formation and cultivation of *Borrelia* spheroplast variants. *Infection* **1996**, *24*, 218–226. [[CrossRef](#)] [[PubMed](#)]
155. Al-Robaigy, S.; Dihazi, H.; Kacza, J.; Seeger, J.; Schiller, J.; Huster, D.; Knauer, J.; Straubinger, R.K. Metamorphosis of *Borrelia burgdorferi* organisms—RNA, lipid and protein composition in context with the spirochetes' shape. *J. Basic Microbiol.* **2010**, *50*, S5–S17. [[CrossRef](#)] [[PubMed](#)]
156. Duray, P.H.; Yin, S.R.; Berzukov, L.; Cox, C.; Cho, M.S.; Fitzgerald, W.; Dorward, D.; Zimmerberg, J.; Margolis, L. Invasion of human tissue ex vivo by *Borrelia burgdorferi*. *J. Infect. Dis.* **2005**, *191*, 1747–1754. [[CrossRef](#)] [[PubMed](#)]
157. Kersten, A.; Poitschek, C.; Rauch, S.; Aberer, E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrob. Agents Chemother.* **1995**, *39*, 1127–1133. [[CrossRef](#)] [[PubMed](#)]
158. Alban, P.S.; Johnson, P.W.; Nelson, D.R. Serum-starvation-induced changes in protein synthesis and morphology of *Borrelia burgdorferi*. *Microbiology* **2000**, *146*, 119–127. [[CrossRef](#)]
159. Brorson, O.; Brorson, S.H. In vitro conversion of *Borrelia burgdorferi* to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. *Infection* **1998**, *26*, 144–150. [[CrossRef](#)]
160. Kraiczy, P.; Hellwage, J.; Skerka, C.; Becker, H.; Kirschfink, M.; Simon, M.M.; Brade, V.; Zipfel, P.F.; Wallich, R. Complement resistance of *Borrelia burgdorferi* correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. *J. Biol. Chem.* **2004**, *279*, 2421–2429. [[CrossRef](#)]
161. Pausa, M.; Pellis, V.; Cinco, M.; Giulianini, P.G.; Presani, G.; Perticarari, S.; Murgia, R.; Tedesco, F. Serum-resistant strains of *Borrelia burgdorferi* evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. *J. Immunol.* **2003**, *170*, 3214–3222. [[CrossRef](#)]
162. Xie, J.; Zhi, H.; Garrigues, R.J.; Keightley, A.; Garcia, B.L.; Skare, J.T. Structural determination of the complement inhibitory domain of *Borrelia burgdorferi* BBK32 provides insight into classical pathway complement evasion by Lyme disease spirochetes. *PLoS Pathog.* **2019**, *15*, e1007659. [[CrossRef](#)]
163. Hartiala, P.; Hytönen, J.; Suhonen, J.; Leppäranta, O.; Tuominen-Gustafsson, H.; Viljanen, M.K. *Borrelia burgdorferi* inhibits human neutrophil functions. *Microbes Infect.* **2008**, *10*, 60–68. [[CrossRef](#)]
164. Hartiala, P.; Hytönen, J.; Pelkonen, J.; Kimppa, K.; West, A.; Penttinen, M.A.; Suhonen, J.; Lahesmaa, R.; Viljanen, M.K. Transcriptional response of human dendritic cells to *Borrelia Garinii*-defective CD38 and CCR7 expression detected. *J. Leukoc. Biol.* **2007**, *82*, 33–43. [[CrossRef](#)] [[PubMed](#)]
165. Tunev, S.S.; Hastey, C.J.; Hodzic, E.; Feng, S.L.; Barthold, S.W.; Baumgarth, N. Lymphadenopathy during Lyme borreliosis is caused by spirochete migration-induced specific B cell activation. *PLoS Pathog.* **2011**, *7*. [[CrossRef](#)] [[PubMed](#)]
166. Hastey, C.J.; Elsner, R.A.; Barthold, S.W.; Baumgarth, N. delays and diversions mark the development of B cell responses to *Borrelia burgdorferi* infection. *J. Immunol.* **2012**, *188*, 5612–5622. [[CrossRef](#)] [[PubMed](#)]
167. Elsner, R.A.; Hastey, C.J.; Baumgarth, N. CD₄ (+) T cells promote antibody production but not sustained affinity maturation during *Borrelia burgdorferi* infection. *Infect. Immun.* **2015**, *83*, 48–56. [[CrossRef](#)]
168. Lazarus, J.J.; Kay, M.A.; McCarter, A.L.; Wooten, R.M. Viable *Borrelia burgdorferi* enhances interleukin-10 production and suppresses activation of murine macrophages. *Infect. Immun.* **2008**, *76*, 1153–1162. [[CrossRef](#)]
169. Giambartolomei, G.H.; Dennis, V.A.; Philipp, M.T. *Borrelia burgdorferi* stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys. *Infect. Immun.* **1998**, *66*, 2691–2697.
170. Feng, J.; Wang, T.; Shi, W.; Zhang, S.; Sullivan, D.; Auwaerter, P.G.; Zhang, Y. Identification of novel activity against *Borrelia burgdorferi* persists using an FDA approved drug library. *Emerg. Microbes Infect.* **2014**, *3*, 1–8. [[CrossRef](#)]
171. Feng, J.; Auwaerter, P.G.; Zhang, Y. Drug combinations against *Borrelia burgdorferi* persists in vitro: Eradication achieved by using daptomycin, cefoperazone and doxycycline. *PLoS ONE* **2015**, *10*, e0117207. [[CrossRef](#)]
172. Feng, J.; Shi, W.; Zhang, S.; Sullivan, D.; Auwaerter, P.G.; Zhang, Y. A drug combination screen identifies drugs active against amoxicillin-induced round bodies of in vitro *Borrelia burgdorferi* persists from an FDA drug library. *Front. Microbiol.* **2016**, *7*, 743. [[CrossRef](#)]
173. Sharma, B.; Brown, A.V.; Matluck, N.E.; Hu, L.T.; Lewis, K. *Borrelia burgdorferi*, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells. *Antimicrob. Agents Chemother.* **2015**, *59*, 4616–4624. [[CrossRef](#)]

174. Feng, J.; Li, T.; Yee, R.; Yuan, Y.; Bai, C.; Cai, M.; Shi, W.; Embers, M.; Brayton, C.; Saeki, H.; et al. Stationary phase persister/biofilm microcolony of *Borrelia burgdorferi* causes more severe disease in a mouse model of Lyme arthritis: Implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure. *Discov. Med.* **2019**, *27*, 125–138. [PubMed]
175. Steere, A.C. Lyme disease. *N. Engl. J. Med.* **1989**, *321*, 586–596. [CrossRef] [PubMed]
176. Steere, A.C.; Malawista, S.E.; Newman, J.H.; Spieler, P.N.; Bartenhagen, N.H. Antibiotic therapy in Lyme disease. *Ann. Intern. Med.* **1980**, *93*, 1–8. [CrossRef] [PubMed]
177. Citera, M.; Freeman, P.R.; Horowitz, R.I. Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease. *Int. J. Gen. Med.* **2017**, *10*, 249–273. [CrossRef] [PubMed]
178. Norris, S.J. Antigenic variation with a twist—the *Borrelia* story. *Mol. Microbiol.* **2006**, *60*, 1319–1322. [CrossRef] [PubMed]
179. Lantos, P.M. Chronic Lyme disease. *Infect. Dis. Clin. N. Am.* **2015**, *29*, 325–340. [CrossRef]
180. Fallon, B.A.; Petkova, E.; Keilp, J.G.; Britton, C.B. A reappraisal of the U.S. Clinical trials of post-treatment Lyme disease syndrome. *Open Neurol. J.* **2012**, *6*, 79–87. [CrossRef]
181. National Institute for Health and Care Excellence (NICE). Lyme Disease: Diagnosis and Management [L] Evidence Review for the Management of Ongoing Symptoms Related to Lyme Disease. NICE Guideline 95 Evidence Review April 2018. Available online: <https://www.nice.org.uk/guidance/ng95/evidence/l-management-of-ongoing-symptoms-related-to-lyme-disease-pdf-172521756184> (accessed on 4 August 2019).
182. Brzonova, I.; Wollenberg, A.; Prinz, J.C. Acrodermatitis chronica atrophicans affecting all four limbs in an 11-year-old girl. *Br. J. Dermatol.* **2002**, *147*, 375–378. [CrossRef]
183. Müller, D.E.; Itin, P.H.; Büchner, S.A.; Rufli, T. Acrodermatitis chronica atrophicans involving the face. Evidence for *Borrelia burgdorferi* infection confirmed by DNA amplification. *Dermatology* **1994**, *189*, 430–431. [CrossRef]
184. Haddad, O.; Gillinov, M.; Fraser, T.; Shrestha, N.; Pettersson, G.B. Mitral Valve Endocarditis: A rare Manifestation of Lyme Disease. *Ann. Thorac. Surg.* **2019**, *108*, e85–e86. [CrossRef]
185. Kempf, W.; Kazakov, D.V.; Hübscher, E.; Gugerli, O.; Gerbig, A.W.; Schmid, R.; Palmedo, G.; Kutzner, H. Cutaneous borreliosis associated with T cell-predominant infiltrates: A diagnostic challenge. *J. Am. Acad. Dermatol.* **2015**, *72*, 683–689. [CrossRef] [PubMed]
186. Leslie, T.A.; Levell, N.J.; Cutler, S.J.; Cann, K.J.; Smith, M.E.; Wright, D.J.; Gilkes, J.J.; Robinson, T.W. Acrodermatitis chronica atrophicans: A case report and review of the literature. *Br. J. Dermatol.* **1994**, *131*, 687–693. [CrossRef] [PubMed]
187. Muellegger, R.R.; Schluepen, E.M.; Millner, M.M.; Soyer, H.P.; Volkenandt, M.; Kerl, H. Acrodermatitis chronica atrophicans in an 11-year-old girl. *Br. J. Dermatol.* **1996**, *135*, 609–612. [CrossRef] [PubMed]
188. Stinco, G.; Trevisan, G.; Martina Patriarca, M.; Ruscio, M.; Di Meo, N.; Patrone, P. Acrodermatitis chronica atrophicans of the face: A case report and a brief review of the literature. *Acta Dermatovenerol. Croat.* **2014**, *22*, 205–208.
189. Da Franca, I.; Santos, L.; Mesquita, T.; Collares-Pereira, M.; Baptista, S.; Vieira, L.; Viana, I.; Vale, E.; Prates, C. Lyme borreliosis in Portugal caused by *Borrelia lusitaniae*? Clinical report on the first patient with a positive skin isolate. *Wien. Klin. Wochenschr.* **2005**, *117*, 429–432. [CrossRef]
190. Zamponi, N.; Cardinali, C.; Tavoni, M.A.; Porfiri, L.; Rossi, R.; Manca, A. Chronic neuroborreliosis in infancy. *Ital. J. Neurol. Sci.* **1999**, *20*, 303–307. [CrossRef]
191. Karma, A.; Pirttila, T.A.; Viljanen, M.K.; Lahde, Y.E.; Raitta, C.M. Secondary retinitis pigmentosa and cerebral demyelination in Lyme borreliosis. *Br. J. Ophthalmol.* **1993**, *77*, 120–122. [CrossRef]
192. Murillo, G.; Ramírez, B.; Romo, L.A.; Muñoz-Sanz, A.; Hileeto, D.; Calonge, M. Oculopalpebral borreliosis as an unusual manifestation of Lyme disease. *Cornea* **2013**, *32*, 87–90. [CrossRef]
193. Oksi, J.; Marjamäki, M.; Koski, K.; Nikoskelainen, J.; Viljanen, M.K. Bilateral facial palsy and meningitis caused by *Borrelia* double infection. *Lancet* **1995**, *345*, 1583–1584. [CrossRef]
194. Oksi, J.; Kalimo, H.; Marttila, R.J.; Marjamäki, M.; Sonninen, P.; Nikoskelainen, J.; Viljanen, M.K. Intracranial aneurysms in three patients with disseminated Lyme borreliosis: Cause or chance association? *J. Neurol. Neurosurg. Psychiatry* **1998**, *64*, 636–642. [CrossRef]
195. Berger, T.G.; Schoerner, C.; Schell, H.; Simon, M.; Schuler, G.; Röllinghoff, M.; Gessner, A. Two unusual cases of diffuse acrodermatitis chronica atrophicans seronegative for Lyme borreliosis. *Eur. J. Clin. Microbiol. Infect. Dis.* **2003**, *22*, 392–395. [CrossRef]
196. Kaufman, L.D.; Gruber, B.L.; Phillips, M.E.; Benach, J.L. Late cutaneous Lyme disease: Acrodermatitis chronica atrophicans. *Am. J. Med.* **1989**, *86*, 828–830. [CrossRef]

197. Maimone, D.; Villanova, M.; Stanta, G.; Bonin, S.; Malandrini, A.; Guazzi, G.C.; Annunziata, P. Detection of *Borrelia burgdorferi* DNA and complement membrane attack complex deposits in the sural nerve of a patient with chronic polyneuropathy and tertiary Lyme disease. *Muscle Nerve* **1997**, *20*, 969–975. [CrossRef]
198. Feder, H.M., Jr.; Abeles, M.; Bernstein, M.; Whitaker-Worth, D.; Grant-Kels, J.M. Diagnosis, treatment, and prognosis of erythema migrans and Lyme arthritis. *Clin. Dermatol.* **2006**, *24*, 509–520. [CrossRef] [PubMed]
199. Karch, H.; Huppertz, H.I. Repeated detection of *Borrelia burgdorferi* DNA in synovial fluid of a child with Lyme arthritis. *Rheumatol. Int.* **1993**, *12*, 227–229. [CrossRef]
200. Snyderman, D.R.; Schenkein, D.P.; Berardi, V.P.; Lastavica, C.C.; Pariser, K.M. *Borrelia burgdorferi* in joint fluid in chronic Lyme arthritis. *Ann. Intern. Med.* **1986**, *104*, 798–800. [CrossRef]
201. Chary-Valckenaere, I.; Jaulhac, B.; Champigneulle, J.; Piemont, Y.; Mainard, D.; Pourel, J. Ultrastructural demonstration of intracellular localization of *Borrelia burgdorferi* in Lyme arthritis. *Br. J. Rheumatol.* **1998**, *37*, 468–470. [CrossRef]
202. Reimers, C.D.; de Koning, J.; Neubert, U.; Preac-Mursic, V.; Koster, J.G.; Müller-Felber, W.; Pongratz, D.E.; Duray, P.H. *Borrelia burgdorferi* myositis: Report of eight patients. *J. Neurol.* **1993**, *240*, 278–283. [CrossRef]
203. Leverkus, M.; Finner, A.M.; Pokrywka, A.; Franke, I.; Gollnick, H. Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. *Dermatology* **2008**, *217*, 215–218. [CrossRef]
204. Miklossy, J.; Khalili, K.; Gern, L.; Ericson, R.L.; Darekar, P.; Bolle, L.; Hurlimann, J.; Paster, B.J. *Borrelia burgdorferi* persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. *J. Alzheimers Dis.* **2004**, *6*, 639–649. [CrossRef]
205. Rigot, E.; Hantz, V.D.; Labrousse, F.; Martin, C.; Dubos, M.; Assikar, S.; Sparsa, A.; Bonnetblanc, J.M.; Bedane, C. Unusual cutaneous manifestations of late Lyme borreliosis. *Eur. J. Dermatol.* **2015**, *25*, 277–279. [CrossRef] [PubMed]
206. Bauvin, O.; Schmutz, J.L.; De Martino, S.; Busato, T.; Cribier, B.; Barbaud, A.; Wahl, D.; Bursztejn, A.C. A foot tumour as late cutaneous Lyme borreliosis: A new entity? *Br. J. Dermatol.* **2017**, *177*, 1127–1130. [CrossRef] [PubMed]
207. Levy, E.; Morrucci, C.; Barbarini, A.; Sordet, C.; Cribier, B.; Jaulhac, B.; Lipsker, D. Clinical images: Toe dactylitis revealing late Lyme borreliosis. *Arthritis Rheum.* **2012**, *64*, 1293. [CrossRef] [PubMed]
208. Matera, G.; Labate, A.; Quirino, A.; Lamberti, A.G.; Borzã, G.; Barreca, G.S.; Mumoli, L.; Peronace, C.; Giancotti, A.; Gambardella, A.; et al. Chronic neuroborreliosis by *B. garinii*: An unusual case presenting with epilepsy and multifocal brain MRI lesions. *New Microbiol.* **2014**, *37*, 393–397.
209. Lobraiko, J.; Butler, A.; Petrini, J.; Ahmadi, R. New insights into stages of Lyme disease symptoms from a novel hospital-based registry. *J. Prim. Care Community Health* **2014**, *5*, 284–287. [CrossRef]
210. Rebman, A.W.; Bechtold, K.T.; Yang, T.; Mihm, E.A.; Soloski, M.J.; Novak, C.B.; Aucott, J.N. The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome. *Front. Med.* **2017**, *4*, 224. [CrossRef]
211. Lantos, P.; Rumbaugh, J.; Bockenstedt, L.; Falck-Ytter, Y.T.; Agüero-Rosenfeld, M.E.; Auwaerter, P.G.; Baldwin, K.; Bannuru, R.; Belani, K.K.; Bowie, W.R.; et al. Bowie WRDraft Clinical Practice Guidelines by the Infectious Diseases Society of 1 America (IDSA), American Academy of Neurology (AAN), and 2 American College of Rheumatology (ACR): 2019 Guidelines for the 3 Prevention, Diagnosis and Treatment of Lyme Disease. Available online: <https://view.protectedpdf.com/ad6GFZ> (accessed on 1 December 2019).
212. Eldin, C.; Jaulhac, B.; Mediannikov, O.; Arzouni, J.P.; Raoult, D. Values of diagnostic tests for the various species of spirochetes. *Med. Mal. Infect.* **2019**, *49*, 102–111. [CrossRef]
213. Schutzer, S.E.; Body, B.A.; Boyle, J.; Branson, B.M.; Dattwyler, R.J.; Fikrig, E.; Gerald, N.J.; Gomes-Solecki, M.; Kintrup, M.; Ledizet, M.; et al. Direct Diagnostic Tests for Lyme Disease. *Clin. Infect. Dis.* **2019**, *68*, 1052–1057. [CrossRef]

